Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNeurotech International Ltd

Neurotech International Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.016 AUD -0.00 ( 5.88%)
Last update at 2026-11-06T05:10:00Z
VOLUME
541837
Market Cap
27.47M

Momentum Score

…

Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.01
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Neurotech International Ltd is an Australia-listed company that appears positioned in the neuroscience and medical-technology sector, focusing on development of therapies and technologies for brain and mental-health conditions. Long-term growth drivers may include unmet clinical need in neurological and psychiatric disorders, progress through clinical and regulatory milestones, and commercialization or partnership deals, which could support future revenue expansion.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
4.73M
Revenue Per Share
0.00
Gross Profit TTM
4.73M
Debt / Equity
-
ROE
-366.75%
Net Debt
-2.39M
ROCE
-1854.26%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -11.27M -10.60M -8.24M -7.79M -3.36M
Net income -6.54M -10.60M -5.07M -7.79M -3.36M
Selling general administrative - 1.21M 2.38M 1.62M 0.62M
Selling and marketing expenses - 0.00M 0.00M 0.01M 0.01M
Gross profit - 2.44M -0.01M 0.01M 0.00M
Reconciled depreciation - 0.00M 0.00M 0.00M 0.00M
Ebit - -10.74M -8.24M -9.05M -3.36M
Ebitda -11.33M -10.74M -8.24M -9.05M -3.36M
Depreciation and amortization - 0.00M 0.00M 0.00M 0.00M
Operating income -11.33M -11.09M -8.76M -7.85M -3.36M
Other operating expenses 11.33M 13.53M 8.76M -8.99M -3.90M
Interest expense - - - - 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.14M 0.16M 0.06M 0.00M
Net interest income - 0.14M 0.16M 0.06M -0.00M
Income tax expense -4.73M - -3.18M -0.06M 0.57M
Total revenue - 2.44M 0.00M 0.01M 0.04M
Total operating expenses 11.33M 13.53M 8.75M 9.06M 3.93M
Cost of revenue - 0.00M 0.01M 0.00M 0.03M
Total other income expense net 0.06M 0.49M 0.52M 1.20M 0.57M
Net income from continuing ops - -10.60M -5.07M -7.79M -3.36M
Net income applicable to common shares - -10.60M -5.07M -7.79M -3.36M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 2.75M 3.24M 12.21M 5.31M 2.02M
Other current assets 0.02M - 0.27M 0.02M 0.02M
Total liab 2.14M 0.29M 0.31M 1.35M 0.59M
Total stockholder equity 0.61M 2.95M 11.90M 3.96M 1.43M
Other current liab 0.07M - 0.04M 0.06M 0.07M
Common stock 52.49M - 46.73M 34.35M 25.78M
Capital stock - 48.91M - 34.35M 25.78M
Retained earnings -58.69M -52.16M -41.56M -36.43M -28.70M
Cash 2.39M 3.03M 2.11M 5.03M 1.90M
Total current liabilities 2.14M 0.29M 0.31M 1.35M 0.59M
Net debt -2.39M - -2.11M -5.03M -1.90M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - - - 0.07M 4.35M
Property plant equipment - - - 0.00M 0.00M
Total current assets 2.75M 3.24M 12.21M 5.31M 2.02M
Net tangible assets - - - 3.96M 1.43M
Short term investments - - 9.52M 2.02M 0.01M
Net receivables 0.34M - 0.32M 0.26M 0.10M
Inventory - - - 0.01M 0.01M
Accounts payable 2.07M 0.22M 0.28M 1.29M 0.52M
Accumulated other comprehensive income 6.81M - 6.72M 6.04M 4.35M
Non currrent assets other - - 0.00M -0.00M -0.00M
Non current assets total - 0.00M 0.00M 0.00M 0.00M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M - - -0.00M
Change to liabilities - - - 0.75M 0.24M
Total cashflows from investing activities - - - 0.00M -0.00M
Total cash from financing activities 3.58M 0.43M 11.19M 9.45M 0.03M
Change to operating activities - - - 0.00M 0.04M
Net income -6.54M -10.60M -5.07M -7.79M -3.36M
Change in cash -0.64M -8.59M 6.60M 3.13M -2.93M
Begin period cash flow 3.03M 11.63M 5.03M 1.90M 4.83M
End period cash flow 2.39M 3.03M 11.63M 5.03M 1.90M
Total cash from operating activities -4.22M -9.02M -4.60M -6.32M -2.96M
Issuance of capital stock - 0.43M 11.19M 9.45M 0.03M
Depreciation - 0.00M 0.00M 0.00M 0.00M
Other cashflows from investing activities - - -4.60M - -
Change to inventory - - 0.01M -0.00M -0.01M
Change to account receivables -0.25M 0.23M -0.06M -0.16M 0.04M
Sale purchase of stock - - - 9.45M 0.03M
Other cashflows from financing activities - - 0.00M - -0.00M
Change to netincome - - - 0.88M 0.08M
Capital expenditures 0.00M 0.00M 4.60M 0.00M 0.00M
Change in working capital 1.70M 0.38M -1.71M -0.16M 0.04M
Stock based compensation - 1.58M 2.18M 0.88M 0.08M
Other non cash items 0.62M -0.38M 2.18M 1.47M 0.29M
Free cash flow -4.22M -9.02M -4.60M -6.32M -2.96M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NTI
Neurotech International Ltd		 -0.00
5.88%		 0.02 - - 5.80 44.95 71058.24 -6.74
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Neurotech International Ltd

Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.

55 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9498 3132

https://neurotechinternational.com

Name Title Year Born
Dr. Alexandra Andrews Chief Operating Officer NA
Prof. Allan Cripps A.O., AO, B.Sc., Ph.D. Chief Scientist & Innovation and Director NA
Dr. Emanuela Russo Chief Scientific Officer & Member of Scientific Advisory Board NA
Mr. Gerald Quigley Director of PR & Director NA
Dr. Thomas Duthy M.B.A., Ph.D. Exec. Director NA
Mr. Peter James Lawrence Griffiths B.Sc. Chief Exec. Officer of AAT Research Ltd 1964
Ms. Erlyn Saromines Dawson A.C.I.S., ACIS, AGIA, B.Com., BCom., GradDipACG Company Sec. NA
Mr. Gerald Quigley Director of Public Relations & Director NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA
Mr. Peter James Lawrence Griffiths B.Sc. Chief Executive Officer of AAT Research Ltd 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…